• 1. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 2. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 3. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

Comprehensive Overview of Tert-butyl 2-bromo-6-azaspiro[3.5]nonane-6-carboxylate (CAS No. 2742657-32-3)

Tert-butyl 2-bromo-6-azaspiro[3.5]nonane-6-carboxylate (CAS No. 2742657-32-3) is a highly specialized organic compound that has garnered significant attention in pharmaceutical and agrochemical research. This spirocyclic compound is characterized by its unique azaspiro[3.5]nonane backbone, which is increasingly being explored for its potential in drug discovery and material science. The presence of a bromo substituent at the 2-position and a tert-butyl carboxylate group at the 6-position makes it a versatile intermediate for further chemical modifications.

In recent years, the demand for spirocyclic compounds like Tert-butyl 2-bromo-6-azaspiro[3.5]nonane-6-carboxylate has surged due to their applications in designing novel small molecule inhibitors and biologically active agents. Researchers are particularly interested in its potential role in targeting G-protein-coupled receptors (GPCRs) and kinase enzymes, which are critical in treating diseases such as cancer and neurodegenerative disorders. The compound's CAS No. 2742657-32-3 is frequently searched in academic databases, reflecting its growing importance in medicinal chemistry.

One of the most discussed topics in the context of Tert-butyl 2-bromo-6-azaspiro[3.5]nonane-6-carboxylate is its synthetic utility. The bromo group serves as an excellent leaving group, enabling nucleophilic substitution reactions, while the tert-butyl carboxylate moiety can be deprotected under mild acidic conditions. This dual functionality allows for the construction of complex molecular architectures, making it a valuable building block in combinatorial chemistry and high-throughput screening.

From an industrial perspective, the scalability of Tert-butyl 2-bromo-6-azaspiro[3.5]nonane-6-carboxylate synthesis is a hot topic. Optimizing reaction conditions to achieve high yields and purity is a key focus area, especially for companies engaged in contract research organizations (CROs) and custom synthesis. The compound's CAS No. 2742657-32-3 is often associated with queries about supplier availability and bulk pricing, indicating its commercial relevance.

Environmental and regulatory considerations are also part of the discourse surrounding Tert-butyl 2-bromo-6-azaspiro[3.5]nonane-6-carboxylate. While the compound is not classified as hazardous, its handling and disposal must adhere to Good Laboratory Practices (GLP) and REACH compliance. Researchers frequently search for safety data sheets (SDS) and storage recommendations to ensure safe usage in laboratories.

In summary, Tert-butyl 2-bromo-6-azaspiro[3.5]nonane-6-carboxylate (CAS No. 2742657-32-3) is a promising compound with multifaceted applications in drug development and material science. Its structural features, synthetic versatility, and commercial potential make it a subject of ongoing research and industrial interest. As the scientific community continues to explore its capabilities, this compound is likely to remain a focal point in organic synthesis and pharmaceutical innovation.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)